Cumberland Pharmaceuticals
CPIX
31 hedge funds and large institutions have $40.1M invested in Cumberland Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 5 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
5% more capital invested
Capital invested by funds: $38.3M → $40.1M (+$1.81M)
0.38% more ownership
Funds ownership: 34.1% → 34.48% (+0.38%)
6% less funds holding
Funds holding: 33 → 31 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $294K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$255K |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
+$169K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$120K |
| 4 |
Renaissance Technologies
New York
|
+$105K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$97.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$296K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$244K |
| 3 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$147K |
| 4 |
BlackRock
New York
|
-$123K |
| 5 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
26
Oakworth Capital
Birmingham,
Alabama
| $22K | – | – | – |
|
27
SEI Investments
Oaks,
Pennsylvania
| $19K | +$1.54K | +210 | +9% |
|
28
UBS Group
Zurich,
Switzerland
| $16K | +$1.02K | +139 | +7% |
|
|
TDC
29
Thompson Davis & Co
Richmond,
Virginia
| $9K | +$9.2K | +1,250 | New |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $5K | +$2.11K | +287 | +66% |
|
|
MA
31
MUFG Americas
New York
| $1K | -$662 | -90 | -39% |
|
|
EIM
32
Essex Investment Management
Boston,
Massachusetts
| – | -$244K | -34,494 | Closed |
|
|
NFA
33
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$27K | -3,851 | Closed |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$8K | -1,114 | Closed |
|
35
Bank of America
Charlotte,
North Carolina
| – | -$1K | -89 | Closed |
|
CPIX Hedge Fund Activity: Q4 2017 in Review
31 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q4 2017, worth a combined $40.1M — up 4.7% from $38.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CPIX and 3 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Stonepine Capital Management, adding an estimated $255K. The largest seller was Invesco, cutting an estimated $296K.
- 31 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q4 2017, down from 33 in Q3 2017.
- Funds reported $40.1M of Cumberland Pharmaceuticals stock for Q4 2017, up 4.7% quarter-over-quarter.
- 3 funds opened new Cumberland Pharmaceuticals positions in Q4 2017 and 5 closed out, a net change of -2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q4 2017 was Stonepine Capital Management, an estimated $255K added.
- The largest Cumberland Pharmaceuticals seller in Q4 2017 was Invesco, an estimated $296K sold.
Based on aggregated 13F filings for Q4 2017.